Alexion/AstraZeneca Deal History & Licensing Activity
Alexion/AstraZeneca is a life sciences. Over the past three years, Alexion/AstraZeneca has been involved in 2 licensing and acquisition transactions, with a primary focus on Gene Therapy (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Gene Therapy
Focus Area
Option Deals
Alexion/AstraZeneca Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Alexion/AstraZeneca in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| AAV-based gene therapy programs (up to 5) | Alexion | Gene Therapy | Preclinical | option | Jun 2025 |
Alexion/AstraZeneca Pipeline Focus
Therapeutic areas and modalities where Alexion/AstraZeneca is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Alexion/AstraZeneca Strategic Signals
Key indicators of Alexion/AstraZeneca's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Alexion/AstraZeneca's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Option Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Mab Benchmarks
Upfront, milestone, and royalty benchmarks for mab deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Alexion/AstraZeneca Licensing & Deal Activity
Alexion/AstraZeneca is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Alexion/AstraZeneca ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Alexion/AstraZeneca include Option Deals (2 deals and trials), and Rare Disease (1 deal and trial). In terms of modality, Alexion/AstraZeneca has shown particular interest in gene therapy, mab.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Alexion/AstraZeneca and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Alexion/AstraZeneca's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.